Lexeo Therapeutics, Company Leadership
| LXEO Stock | 3.38 0.35 9.38% |
Lexeo Therapeutics, employs about 72 people. The company is managed by 13 executives with a total tenure of roughly 168 years, averaging almost 12.0 years of service per executive, having 5.54 employees per reported executive. Analysis of Lexeo Therapeutics,'s management performance can provide insight into the firm performance.
Lexeo |
Lexeo Therapeutics, Management Team Effectiveness
The company has return on total asset (ROA) of (0.3993) % which means that it has lost $0.3993 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7483) %, meaning that it created substantial loss on money invested by shareholders. Lexeo Therapeutics,'s management efficiency ratios could be used to measure how well Lexeo Therapeutics, manages its routine affairs as well as how well it operates its assets and liabilities.Lexeo Therapeutics, Workforce Comparison
Lexeo Therapeutics, Common is currently regarded as number one stock in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 18,497. Lexeo Therapeutics, adds roughly 72.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Lexeo Therapeutics, Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Lexeo Therapeutics, insiders, such as employees or executives, is commonly permitted as long as it does not rely on Lexeo Therapeutics,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Lexeo Therapeutics, insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Jenny Robertson six days ago Disposition of 2101 shares by Jenny Robertson of Lexeo Therapeutics, at 4.413 subject to Rule 16b-3 | ||
Rasbach Kyle over a month ago Acquisition by Rasbach Kyle of 40875 shares of Lexeo Therapeutics, subject to Rule 16b-3 | ||
Omega Fund Vi, L.p. over a month ago Acquisition by Omega Fund Vi, L.p. of 287213 shares of Lexeo Therapeutics, subject to Rule 16b-3 | ||
Rasbach Kyle over two months ago Insider Trading | ||
Cholmondeley Paula H over three months ago Acquisition by Cholmondeley Paula H of 15000 shares of Lexeo Therapeutics, at 6.9901 subject to Rule 16b-3 | ||
Tanguler Tolga over three months ago Insider Trading | ||
Townsend Richard Nolan over three months ago Disposition of 5000 shares by Townsend Richard Nolan of Lexeo Therapeutics, at 8.0991 subject to Rule 16b-3 | ||
Townsend Richard Nolan over three months ago Disposition of 5000 shares by Townsend Richard Nolan of Lexeo Therapeutics, at 10.6547 subject to Rule 16b-3 |
Lexeo Therapeutics, Notable Stakeholders
A Lexeo Therapeutics, stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Lexeo Therapeutics, often face trade-offs trying to please all of them. Lexeo Therapeutics,'s stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Lexeo Therapeutics,'s stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Ronald MD | Chief CoFounder | Profile | |
| Nolan Townsend | CEO Director | Profile | |
| Ryan McHenry | VP Controller | Profile | |
| Rand Monaghan | Vice Finance | Profile | |
| Paul McCormac | Chief Officer | Profile | |
| Jordan MD | Cardiology Science | Profile | |
| Jenny Robertson | Chief Officer | Profile | |
| Sandi MD | Senior Operations | Profile | |
| PharmD Rasbach | Chief Officer | Profile | |
| Jose Otero | Chief Officer | Profile | |
| Eric MD | Chief Research | Profile | |
| Jenny JD | Chief Officer | Profile | |
| Micah Zajic | Chief Officer | Profile |
About Lexeo Therapeutics, Management Performance
The success or failure of an entity such as Lexeo Therapeutics, often depends on how effective the management is. Lexeo Therapeutics, management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Lexeo management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Lexeo management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Lexeo Therapeutics, Workforce Analysis
Traditionally, organizations such as Lexeo Therapeutics, use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Lexeo Therapeutics, within its industry.Lexeo Therapeutics, Manpower Efficiency
Return on Lexeo Therapeutics, Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 922.1K | |
| Net Loss Per Executive | 5.1M | |
| Working Capital Per Employee | 1.5M | |
| Working Capital Per Executive | 8.2M |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lexeo Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lexeo Therapeutics,. If investors know Lexeo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lexeo Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Lexeo Therapeutics, is measured differently than its book value, which is the value of Lexeo that is recorded on the company's balance sheet. Investors also form their own opinion of Lexeo Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Lexeo Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lexeo Therapeutics,'s market value can be influenced by many factors that don't directly affect Lexeo Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lexeo Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Lexeo Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lexeo Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.